1. active illicit or non-prescribed drug use. 2. concomitant use of benzodiazepines. 3. concomitant use of an immune suppressant agent, e.g., prednisone. 4. documented history and active treatment for seizure disorder. 5. transaminase elevation. 6. active autoimmune disorder. 7. hepatitis c infection (currently on therapy and/or any transaminitis elevation). 8. hepatitis b infection (currently on therapy and/or any transaminitis elevation). 9. human immune deficiency virus (hiv-1 or hiv-2) infection that is newly diagnosed or untreated. 10. any form of mental impairment that will/could hinder safe participation in the study. 11. pregnancy or breast-feeding. 12. any condition that in the opinion of the investigator would be harmful or detrimental to the participant.

1. active illicit or non-prescribed drug use. 2. concomitant use of benzodiazepines. 3. concomitant use of an immune suppressant agent, e.g., prednisone. 4. documented history and active treatment for seizure disorder. 5. transaminase elevation. 6. active autoimmune disorder. 7. hepatitis c infection (currently on therapy and/or any transaminitis elevation). 8. hepatitis b infection (currently on therapy and/or any transaminitis elevation). 9. human immune deficiency virus (hiv-1 or hiv-2) infection that is newly diagnosed or untreated. 10. any form of mental impairment that will/could hinder safe participation in the study. 11. pregnancy or breast-feeding. 12. any condition that in the opinion of the investigator would be harmful or detrimental to the participant.

active illicit or non-prescribed drug use. concomitant use of benzodiazepines. concomitant use of an immune suppressant agent, e.g., prednisone. documented history and active treatment for seizure disorder. transaminase elevation. active autoimmune disorder. hepatitis c infection (currently on therapy and/or any transaminitis elevation). hepatitis b infection (currently on therapy and/or any transaminitis elevation). human immune deficiency virus (hiv-1 or hiv-2) infection that is newly diagnosed or untreated. any form of mental impairment that will/could hinder safe participation in the study. pregnancy or breast-feeding. any condition that in the opinion of the investigator would be harmful or detrimental to the participant.

active illicit or non-prescribed drug use. concomitant use of benzodiazepines. concomitant use of an immune suppressant agent, e.g., prednisone. documented history and active treatment for seizure disorder. transaminase elevation. active autoimmune disorder. hepatitis c infection (currently on therapy and/or any transaminitis elevation). hepatitis b infection (currently on therapy and/or any transaminitis elevation). human immune deficiency virus (hiv-1 or hiv-2) infection that is newly diagnosed or untreated. any form of mental impairment that will/could hinder safe participation in the study. pregnancy or breast-feeding. any condition that in the opinion of the investigator would be harmful or detrimental to the participant.

1. active illicit or non-prescribed drug use. 2. concomitant use of benzodiazepines. 3. concomitant use of an immune suppressant agent, e.g., prednisone. 4. documented history and active treatment for seizure disorder. 5. transaminase elevation. 6. active autoimmune disorder. 7. hepatitis c infection (currently on therapy and/or any transaminitis elevation). 8. hepatitis b infection (currently on therapy and/or any transaminitis elevation). 9. human immune deficiency virus (hiv-1 or hiv-2) infection that is newly diagnosed or untreated. 10. any form of mental impairment that will/could hinder safe participation in the study. 11. pregnancy or breast-feeding. 12. any condition that in the opinion of the investigator would be harmful or detrimental to the participant.

1. active illicit or non-prescribed drug use. 2. concomitant use of benzodiazepines. 3. concomitant use of an immune suppressant agent, e.g., prednisone. 4. documented history and active treatment for seizure disorder. 5. transaminase elevation. 6. active autoimmune disorder. 7. hepatitis c infection (currently on therapy and/or any transaminitis elevation). 8. hepatitis b infection (currently on therapy and/or any transaminitis elevation). 9. human immune deficiency virus (hiv-1 or hiv-2) infection that is newly diagnosed or untreated. 10. any form of mental impairment that will/could hinder safe participation in the study. 11. pregnancy or breast-feeding. 12. any condition that in the opinion of the investigator would be harmful or detrimental to the participant.